chemical genetics strategy identifies hcv ns5a inhibitor potent clinical effect 
worldwide prevalence chronic hepatitis c virus hcv infection estimated approaching million people current therapy relies upon combination pegylated interferon-alpha ribavirin poorly tolerated regimen typically associated less % sustained virological response rate infected genotype virus development direct-acting antiviral agents treat hcv focused predominantly inhibitors viral enzymes ns3 protease rna-dependent-rna polymerase ns5b describe profile bms- small molecule inhibitor hcv ns5a protein exhibits picomolar half-maximum effective concentrations ec towards replicons expressing broad range hcv genotypes jfh genotype 2a infectious virus cell culture phase clinical trial patients chronically infected hcv administration single mg dose bms associated log reduction mean viral load measured h post-dose sustained additional h two patients infected genotype 1b virus genotypic analysis samples taken baseline h post-dose revealed major hcv variants observed substitutions amino-acid positions identified using vitro replicon system results provide first clinical validation inhibitor hcv ns5a protein known enzymatic function approach suppression virus replication offers potential part therapeutic regimen based combinations hcv inhibitors 
